Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SMLR vs MDXG vs NAUT vs BEAT vs BFLY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SMLR
Semler Scientific, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$311M
5Y Perf.-78.9%
MDXG
MiMedx Group, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$548M
5Y Perf.-3.4%
NAUT
Nautilus Biotechnology, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$366M
5Y Perf.-59.8%
BEAT
HeartBeam, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$35M
5Y Perf.-32.8%
BFLY
Butterfly Network, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.11B
5Y Perf.-46.1%

SMLR vs MDXG vs NAUT vs BEAT vs BFLY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SMLR logoSMLR
MDXG logoMDXG
NAUT logoNAUT
BEAT logoBEAT
BFLY logoBFLY
IndustryMedical - DevicesBiotechnologyBiotechnologyMedical - Healthcare Information ServicesMedical - Devices
Market Cap$311M$548M$366M$35M$1.11B
Revenue (TTM)$37M$389M$0.00$0.00$103M
Net Income (TTM)$48M$31M$-57M$-21M$-76M
Gross Margin90.8%81.0%49.2%
Operating Margin-94.7%10.2%-79.5%
Forward P/E4.0x295.2x
Total Debt$70K$23M$30M$0.00$20M
Cash & Equiv.$9M$166M$12M$4M$150M

SMLR vs MDXG vs NAUT vs BEAT vs BFLYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SMLR
MDXG
NAUT
BEAT
BFLY
StockNov 21Jan 26Return
Semler Scientific, … (SMLR)10021.1-78.9%
MiMedx Group, Inc. (MDXG)10096.6-3.4%
Nautilus Biotechnol… (NAUT)10040.2-59.8%
HeartBeam, Inc. (BEAT)10067.2-32.8%
Butterfly Network, … (BFLY)10053.9-46.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: SMLR vs MDXG vs NAUT vs BEAT vs BFLY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDXG leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Semler Scientific, Inc. is the stronger pick specifically for valuation and capital efficiency and profitability and margin quality. NAUT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SMLR
Semler Scientific, Inc.
The Value Play

SMLR is the #2 pick in this set and the best alternative if value and quality is your priority.

  • Better valuation composite
  • 130.8% margin vs BFLY's -73.6%
Best for: value and quality
MDXG
MiMedx Group, Inc.
The Income Pick

MDXG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.22
  • Rev growth 20.0%, EPS growth 14.3%, 3Y rev CAGR 16.1%
  • -48.5% 10Y total return vs SMLR's 11.1%
  • Lower volatility, beta 1.22, Low D/E 8.8%, current ratio 4.32x
Best for: income & stability and growth exposure
NAUT
Nautilus Biotechnology, Inc.
The Momentum Pick

NAUT ranks third and is worth considering specifically for momentum.

  • +311.5% vs BEAT's -53.7%
Best for: momentum
BEAT
HeartBeam, Inc.
The Healthcare Pick

BEAT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
BFLY
Butterfly Network, Inc.
The Healthcare Pick

Among these 5 stocks, BFLY doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthMDXG logoMDXG20.0% revenue growth vs BEAT's -100.0%
ValueSMLR logoSMLRBetter valuation composite
Quality / MarginsSMLR logoSMLR130.8% margin vs BFLY's -73.6%
Stability / SafetyMDXG logoMDXGBeta 1.22 vs BFLY's 3.28, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)NAUT logoNAUT+311.5% vs BEAT's -53.7%
Efficiency (ROA)MDXG logoMDXG9.7% ROA vs BEAT's -353.1%

SMLR vs MDXG vs NAUT vs BEAT vs BFLY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SMLRSemler Scientific, Inc.

Segment breakdown not available.

MDXGMiMedx Group, Inc.
FY 2025
Surgical
100.0%$142M
NAUTNautilus Biotechnology, Inc.

Segment breakdown not available.

BEATHeartBeam, Inc.
FY 2019
MonitoringCommercial
49.7%$218M
MonitoringMedicare
35.0%$154M
ClinicalTrialSupportandRelatedServices
12.4%$54M
TechnologyDevicesConsumablesandRelatedServices
2.9%$13M
BFLYButterfly Network, Inc.
FY 2025
Product
65.0%$63M
Software And Other Services
35.0%$34M

SMLR vs MDXG vs NAUT vs BEAT vs BFLY — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDXGLAGGINGBFLY

Income & Cash Flow (Last 12 Months)

SMLR leads this category, winning 3 of 6 comparable metrics.

MDXG and BEAT operate at a comparable scale, with $389M and $0 in trailing revenue. SMLR is the more profitable business, keeping 130.8% of every revenue dollar as net income compared to BFLY's -73.6%. On growth, BFLY holds the edge at +25.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSMLR logoSMLRSemler Scientific…MDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…BEAT logoBEATHeartBeam, Inc.BFLY logoBFLYButterfly Network…
RevenueTrailing 12 months$37M$389M$0$0$103M
EBITDAEarnings before interest/tax-$35M$53M-$58M-$21M-$76M
Net IncomeAfter-tax profit$48M$31M-$57M-$21M-$76M
Free Cash FlowCash after capex-$389M$66M-$51M-$15M-$19M
Gross MarginGross profit ÷ Revenue+90.8%+81.0%+49.2%
Operating MarginEBIT ÷ Revenue-94.7%+10.2%-79.5%
Net MarginNet income ÷ Revenue+130.8%+7.9%-73.6%
FCF MarginFCF ÷ Revenue-10.5%+17.0%-18.3%
Rev. Growth (YoY)Latest quarter vs prior year-44.6%-33.1%+25.0%
EPS Growth (YoY)Latest quarter vs prior year+48.6%-2.4%+7.7%+22.2%+16.0%
SMLR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MDXG leads this category, winning 2 of 4 comparable metrics.

At 4.0x trailing earnings, SMLR trades at a 66% valuation discount to MDXG's 11.5x P/E. On an enterprise value basis, MDXG's 5.1x EV/EBITDA is more attractive than SMLR's 14.0x.

MetricSMLR logoSMLRSemler Scientific…MDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…BEAT logoBEATHeartBeam, Inc.BFLY logoBFLYButterfly Network…
Market CapShares × price$311M$548M$366M$35M$1.1B
Enterprise ValueMkt cap + debt − cash$302M$405M$384M$31M$979M
Trailing P/EPrice ÷ TTM EPS3.96x11.53x-6.13x-1.40x-13.68x
Forward P/EPrice ÷ next-FY EPS est.295.20x
PEG RatioP/E ÷ EPS growth rate0.18x
EV / EBITDAEnterprise value multiple14.04x5.14x
Price / SalesMarket cap ÷ Revenue5.52x1.31x11.37x
Price / BookPrice ÷ Book value/share0.70x2.15x2.32x11.27x5.35x
Price / FCFMarket cap ÷ FCF7.51x
MDXG leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

MDXG leads this category, winning 7 of 9 comparable metrics.

MDXG delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-6 for BEAT. SMLR carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NAUT's 0.19x. On the Piotroski fundamental quality scale (0–9), MDXG scores 5/9 vs BEAT's 1/9, reflecting solid financial health.

MetricSMLR logoSMLRSemler Scientific…MDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…BEAT logoBEATHeartBeam, Inc.BFLY logoBFLYButterfly Network…
ROE (TTM)Return on equity+10.5%+12.9%-35.0%-5.7%-36.8%
ROA (TTM)Return on assets+8.1%+9.7%-29.2%-3.5%-25.6%
ROICReturn on invested capital+13.3%+42.3%-26.0%-76.8%
ROCEReturn on capital employed+13.7%+25.7%-32.0%-4.6%-39.3%
Piotroski ScoreFundamental quality 0–945113
Debt / EquityFinancial leverage0.00x0.09x0.19x0.10x
Net DebtTotal debt minus cash-$9M-$144M$18M-$4M-$130M
Cash & Equiv.Liquid assets$9M$166M$12M$4M$150M
Total DebtShort + long-term debt$70,000$23M$30M$0$20M
Interest CoverageEBIT ÷ Interest expense-12.85x25.32x-71.59x
MDXG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — NAUT and BFLY each lead in 2 of 6 comparable metrics.

A $10,000 investment in MDXG five years ago would be worth $3,712 today (with dividends reinvested), compared to $1,815 for SMLR. Over the past 12 months, NAUT leads with a +311.5% total return vs BEAT's -53.7%. The 3-year compound annual growth rate (CAGR) favors BFLY at 26.2% vs BEAT's -25.8% — a key indicator of consistent wealth creation.

MetricSMLR logoSMLRSemler Scientific…MDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…BEAT logoBEATHeartBeam, Inc.BFLY logoBFLYButterfly Network…
YTD ReturnYear-to-date+14.3%-43.1%+50.8%-64.2%+13.1%
1-Year ReturnPast 12 months-38.5%-47.1%+311.5%-53.7%+94.5%
3-Year ReturnCumulative with dividends-18.9%-36.6%+21.0%-59.1%+100.9%
5-Year ReturnCumulative with dividends-81.8%-62.9%-71.3%-81.4%-65.1%
10-Year ReturnCumulative with dividends+1110.1%-48.5%-72.4%-81.4%-57.2%
CAGR (3Y)Annualised 3-year return-6.8%-14.1%+6.6%-25.8%+26.2%
Evenly matched — NAUT and BFLY each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MDXG and BFLY each lead in 1 of 2 comparable metrics.

MDXG is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than BFLY's 3.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BFLY currently trades 74.1% from its 52-week high vs BEAT's 21.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSMLR logoSMLRSemler Scientific…MDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…BEAT logoBEATHeartBeam, Inc.BFLY logoBFLYButterfly Network…
Beta (5Y)Sensitivity to S&P 5002.48x1.22x1.82x1.24x3.28x
52-Week HighHighest price in past year$50.44$7.99$4.31$4.00$5.72
52-Week LowLowest price in past year$14.88$3.02$0.62$0.54$1.32
% of 52W HighCurrent price vs 52-week peak+40.3%+46.2%+66.8%+21.8%+74.1%
RSI (14)Momentum oscillator 0–10052.449.352.537.346.2
Avg Volume (50D)Average daily shares traded01.4M315K1.6M6.4M
Evenly matched — MDXG and BFLY each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: SMLR as "Buy", MDXG as "Buy", NAUT as "Buy", BFLY as "Buy". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs -13.2% for NAUT (target: $3).

MetricSMLR logoSMLRSemler Scientific…MDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…BEAT logoBEATHeartBeam, Inc.BFLY logoBFLYButterfly Network…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$50.50$10.00$2.50$5.42
# AnalystsCovering analysts71557
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.6%0.0%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

MDXG leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). SMLR leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMiMedx Group, Inc. (MDXG)Leads 2 of 6 categories
Loading custom metrics...

SMLR vs MDXG vs NAUT vs BEAT vs BFLY: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SMLR or MDXG or NAUT or BEAT or BFLY a better buy right now?

For growth investors, MiMedx Group, Inc.

(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus -17. 4% for Semler Scientific, Inc. (SMLR). Semler Scientific, Inc. (SMLR) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate Semler Scientific, Inc. (SMLR) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SMLR or MDXG or NAUT or BEAT or BFLY?

On trailing P/E, Semler Scientific, Inc.

(SMLR) is the cheapest at 4. 0x versus MiMedx Group, Inc. at 11. 5x.

03

Which is the better long-term investment — SMLR or MDXG or NAUT or BEAT or BFLY?

Over the past 5 years, MiMedx Group, Inc.

(MDXG) delivered a total return of -62. 9%, compared to -81. 8% for Semler Scientific, Inc. (SMLR). Over 10 years, the gap is even starker: SMLR returned +1110% versus BEAT's -81. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SMLR or MDXG or NAUT or BEAT or BFLY?

By beta (market sensitivity over 5 years), MiMedx Group, Inc.

(MDXG) is the lower-risk stock at 1. 22β versus Butterfly Network, Inc. 's 3. 28β — meaning BFLY is approximately 169% more volatile than MDXG relative to the S&P 500. On balance sheet safety, Semler Scientific, Inc. (SMLR) carries a lower debt/equity ratio of 0% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SMLR or MDXG or NAUT or BEAT or BFLY?

By revenue growth (latest reported year), MiMedx Group, Inc.

(MDXG) is pulling ahead at 20. 0% versus -17. 4% for Semler Scientific, Inc. (SMLR). On earnings-per-share growth, the picture is similar: Semler Scientific, Inc. grew EPS 95. 1% year-over-year, compared to 8. 8% for Butterfly Network, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SMLR or MDXG or NAUT or BEAT or BFLY?

Semler Scientific, Inc.

(SMLR) is the more profitable company, earning 72. 7% net margin versus -79. 0% for Butterfly Network, Inc. — meaning it keeps 72. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMLR leads at 37. 2% versus -88. 5% for BFLY. At the gross margin level — before operating expenses — SMLR leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SMLR or MDXG or NAUT or BEAT or BFLY more undervalued right now?

Analyst consensus price targets imply the most upside for MDXG: 171.

0% to $10. 00.

08

Which pays a better dividend — SMLR or MDXG or NAUT or BEAT or BFLY?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SMLR or MDXG or NAUT or BEAT or BFLY better for a retirement portfolio?

For long-horizon retirement investors, Semler Scientific, Inc.

(SMLR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1110% 10Y return). Butterfly Network, Inc. (BFLY) carries a higher beta of 3. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SMLR: +1110%, BFLY: -57. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SMLR and MDXG and NAUT and BEAT and BFLY?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SMLR is a small-cap deep-value stock; MDXG is a small-cap high-growth stock; NAUT is a small-cap quality compounder stock; BEAT is a small-cap quality compounder stock; BFLY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SMLR

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 78%
Run This Screen
Stocks Like

MDXG

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

NAUT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

BEAT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

BFLY

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Gross Margin > 29%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SMLR and MDXG and NAUT and BEAT and BFLY on the metrics below

Revenue Growth>
%
(SMLR: -44.6% · MDXG: -33.1%)
Net Margin>
%
(SMLR: 130.8% · MDXG: 7.9%)
P/E Ratio<
x
(SMLR: 4.0x · MDXG: 11.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.